Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis

J. Sarin, S. S. DeRossi, S. O. Akintoye

Research output: Contribution to journalReview article

88 Citations (Scopus)

Abstract

Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia®) and zoledronic acid (Zometa®), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.

Original languageEnglish (US)
Pages (from-to)277-285
Number of pages9
JournalOral Diseases
Volume14
Issue number3
DOIs
StatePublished - Apr 1 2008

Fingerprint

zoledronic acid
pamidronate
Bisphosphonate-Associated Osteonecrosis of the Jaw
Diphosphonates
Osteonecrosis
Jaw
Guidelines

Keywords

  • Biology
  • Bisphosphonates
  • Bone marrow
  • Jaw
  • Osteonecrosis

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. / Sarin, J.; DeRossi, S. S.; Akintoye, S. O.

In: Oral Diseases, Vol. 14, No. 3, 01.04.2008, p. 277-285.

Research output: Contribution to journalReview article

Sarin, J. ; DeRossi, S. S. ; Akintoye, S. O. / Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. In: Oral Diseases. 2008 ; Vol. 14, No. 3. pp. 277-285.
@article{cca9b4ff2df949a8ba296f8cbd466c53,
title = "Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis",
abstract = "Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia{\circledR}) and zoledronic acid (Zometa{\circledR}), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.",
keywords = "Biology, Bisphosphonates, Bone marrow, Jaw, Osteonecrosis",
author = "J. Sarin and DeRossi, {S. S.} and Akintoye, {S. O.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1111/j.1601-0825.2007.01381.x",
language = "English (US)",
volume = "14",
pages = "277--285",
journal = "Oral Diseases",
issn = "1354-523X",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis

AU - Sarin, J.

AU - DeRossi, S. S.

AU - Akintoye, S. O.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia®) and zoledronic acid (Zometa®), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.

AB - Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia®) and zoledronic acid (Zometa®), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.

KW - Biology

KW - Bisphosphonates

KW - Bone marrow

KW - Jaw

KW - Osteonecrosis

UR - http://www.scopus.com/inward/record.url?scp=40749119721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749119721&partnerID=8YFLogxK

U2 - 10.1111/j.1601-0825.2007.01381.x

DO - 10.1111/j.1601-0825.2007.01381.x

M3 - Review article

C2 - 18336375

AN - SCOPUS:40749119721

VL - 14

SP - 277

EP - 285

JO - Oral Diseases

JF - Oral Diseases

SN - 1354-523X

IS - 3

ER -